OBJECTIVE： To investigate the correlation of gene polymorphism in peripheral artery disease （PAD） patients with antiplatelet efficacy of clopidogrel. METHODS： Reviewing related domestic and foreign literatures in recent years， the correlation of gene polymorphism in PAD patients with antiplatelet efficacy of clopidogrel was summarized and analyzed. RESULTS&CONCLUSIONS： At present， a variety of genes associated with clopidogrel antiplatelet efficacy and major adverse cardiovascular events （MACE） have been identified， including cytochrome P450 （CYP） 2C19， adenosine three phosphate binding cassette B subfamily 1 （ABCB1）， paraoxonase 1 （PON1） and adenosine diphosphate P2Y12 receptor （P2Y12）， etc. CYP2C19*2， *3 allele may reduce the antiplatelet effect of clopidogrel. Their correlation has been confirmed by a number of studies， and study results are broadly consistent. Mutations in the ABCB1 C3435T and PON1 Q192R sites may lead to a lower response to clopidogrel and increase the risk of MACE； but there is a lack of large-scale prospective clinical studies， and the present results are inconsistent. P2Y12 gene polymorphism in PAD patients has not been found to be significantly associated with clopidogrel efficacy.